The news: Eli Lilly is acquiring psychedelic drug developer AtaiBeckley in a deal valued at $3.8 billion, making it the largest psychedelic pharma acquisition to date. AtaiBeckley is developing a DMT-based nasal spray for depression after the FDA granted it expedited review last year.

Why it matters: Lilly's acquisition is another sign that psychedelics are becoming an established area of pharma research and development. As the world's largest pharmaceutical company, its acquisition further legitimizes psychedelics as a drug class and could spur broader industry investment. The deal comes as the Trump administration pushes the FDA to accelerate drug reviews, expand federal support for psychedelic research, and advance regulatory guidance for psychedelic therapies.

Until now, the FDA has approved only one psychedelic-derived treatment (Johnson & Johnson's Spravato), and rejected Lykos Pharmaceuticals' MDMA-assisted therapy in 2024. Taken together, the newer developments point to a more supportive regulatory environment for psychedelic drug development, even as the category remains in its early stages.

Implications for pharma and healthcare providers: Commercialization of psychedelic drugs will look very different from a traditional drug launch. Because these therapies are administered under provider supervision, success will depend as much on building care delivery as on the drug itself. Pharma companies will need site-of-care strategies, provider education, reimbursement planning, and patient monitoring, not just marketing.

Healthcare providers and systems will also need to expand treatment capacity by creating monitored dosing spaces, training staff on administration protocols, and integrating psychedelic therapies with psychotherapy and follow-up care.

This content is part of EMARKETER’s subscription Briefings, where we pair daily updates with data and analysis from forecasts and research reports. Our Briefings prepare you to start your day informed, to provide critical insights in an important meeting, and to understand the context of what’s happening in your industry. Not a subscriber? Click here to get a demo of our full platform and coverage.